Ardelyx (FRA:41X) 3-Year Book Growth Rate : 4.70% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx 3-Year Book Growth Rate?

Ardelyx's Book Value per Share for the quarter that ended in Dec. 2024 was €0.70.

During the past 12 months, Ardelyx's average Book Value per Share Growth Rate was 1.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was 4.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -19.20% per year. During the past 10 years, the average Book Value per Share Growth Rate was -19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Ardelyx was 4.70% per year. The lowest was -38.20% per year. And the median was -21.35% per year.

Competitive Comparison of Ardelyx's 3-Year Book Growth Rate

For the Biotechnology subindustry, Ardelyx's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ardelyx's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Ardelyx's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Ardelyx 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Ardelyx (FRA:41X) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Ardelyx 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Ardelyx's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ARDX:USA

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines